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Abstract The aim of the present paper was to examine, in
a comparative way, the occurrence and the mechanisms of
the interactions between adenosine A2A receptors (A2ARs)
and metabotropic glutamate 5 receptors (mGlu5Rs) in the
hippocampus and the striatum. In rat hippocampal and
corticostriatal slices, combined ineffective doses of the
mGlu5R agonist 2-chloro-5-hydroxyphenylglycine (CHPG)
and the A2AR agonist CGS 21680 synergistically reduced
the slope of excitatory postsynaptic field potentials
(fEPSPs) recorded in CA1 and the amplitude of field
potentials (FPs) recorded in the dorsomedial striatum. The
cyclic adenosine monophosphate (cAMP)/protein kinase A
(PKA) pathway appeared to be involved in the effects of
CGS 21680 in corticostriatal but not in hippocampal slices.
In both areas, a postsynaptic locus of interaction appeared
more likely. N-methyl-D-aspartate (NMDA) reduced the
fEPSP slope and FP amplitude in hippocampal and
corticostriatal slices, respectively. Such an effect was
significantly potentiated by CHPG in both areas. Interest-
ingly, the A2AR antagonist ZM 241385 significantly
reduced the NMDA-potentiating effect of CHPG. In
primary cultures of rat hippocampal and striatal neurons
(ED 17, DIV 14), CHPG significantly potentiated NMDA-
induced lactate dehydrogenase (LDH) release. Again, such
an effect was prevented by ZM 241385. Our results show
that A2A and mGlu5 receptors functionally interact both in
the hippocampus and in the striatum, even though different
mechanisms seem to be involved in the two areas. The
ability of A2ARs to control mGlu5R-dependent effects may
thus be a general feature of A2ARs in different brain regions
(irrespective of their density) and may represent an
additional target for the development of therapeutic
strategies against neurological disorders.






Adenosine A2A receptors (A2ARs) are the most abundant
adenosine receptor subtypes in the striatum, where they
play a prominent role in modulating glutamatergic input to
striatal GABAergic neurons. These receptors are almost
exclusively localized in the striopallidal neurons, which
also show a high degree of expression of metabotropic
glutamate 5 receptors (mGlu5Rs) [1]. It has been previously
demonstrated that mGlu5Rs are particularly involved in the
modulation of striatal functions such as motor activity [2]
and synaptic plasticity [3] and that they play a role in
neurodegenerative processes [4]. Functional interactions
between striatal mGlu5Rs and A2ARs have been reported in
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e-mail: tebano@iss.itthe modulation of several effects, such as motor behavior in
models of Parkinson’s disease [2, 5, 6], +-aminobutyric acid
(GABA) and glutamate release [7, 8], c-fos expression [9],
and DARPP-32 phosphorylation [10]. Such functional
interactions were supported by the demonstration of the
existence of heteromeric complexes containing A2A and
mGlu5 receptors in striatal neurons [9].
Although adenosine A2A receptors are mostly expressed
in the striatum, a limited degree of expression also exists in
the hippocampus, where such receptors exert an excitatory
influence on normal synaptic transmission and modulate
excitotoxic processes [11]. Like the striatum, the hippo-
campus shows a marked expression of mGlu5Rs (mainly
located in the CA1 area), which, by setting the tone of
N-methyl-D-aspartate (NMDA) receptors [12–14], mediate
several physiological and pathological processes such as
learning and memory [15, 16], generation of epileptic
activity [17], and excitotoxicity [18]. Very recently, we
have demonstrated that A2A and mGlu5Rs are colocalized
in the rat hippocampus [19].
The activation of A2A receptors facilitates
mGlu5R–mediated responses in both striatal
and hippocampal preparations
Electrophysiological experiments were performed in both
corticostriatal and hippocampal slices from rats as previ-
ously described [19, 20]. Extracellular field excitatory post-
synaptic potentials (fEPSPs) and extracellular field potentials
(FPs) were recorded in the stratum radiatum of the CA1 area
orinthedorsomedialstriatum.Toallowcomparisonsbetween
different experiments, in each experiment the values of the
fEPSPs slope and of the FP amplitude were normalized,
taking as 100% the average of the control values. The se-
lective mGlu5R agonist 2-chloro-5-hydroxyphenylglycine
(CHPG)didnotaffectthe electricalresponsesofhippocampal
and striatal neurons at μM concentrations. As shown in
Figure1a, onlyatconcentrationsof1mMdidCHPGinducea
reductionofthefEPSPsslopeinthehippocampus(-21.8±4%
of basal) and of the FP amplitude in the striatum (-15.7 ±
5.4%); in both cases, CHPG-induced reductions completely
Figure 1 Adenosine A2A acti-
vation facilitates CHPG-induced
effects in hippocampal and cor-
ticostriatal slices. Superfusion of
rat hippocampal and cortico-
striatal slices with the selective
mGlu5R agonist CHPG (1 mM)
induced a comparable decrease
of the fEPSP slope and FP
amplitude that recovered after
washing (a). The co-application
of concentrations of CGS 21680
(50 nM) and CHPG
(500–750 μM), which were in-
effective by themselves, signifi-
cantly reduced the fEPSP slope
in hippocampal slices and the
FP amplitude in corticostriatal
slices (b). The graphs represent
the average time course of
changes in the fEPSP slope (N =
6–13 experiments) and FP am-
plitude (N =1 0 –15 experi-
ments). All the values are
expressed as percentage of
baseline values (mean ± SEM).
The period of drug application is
indicated by the horizontal bars
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cantly reduced by the selective mGlu5R antagonist MPEP
(30–50 μM) in both the hippocampus and the striatum
(MPEP + CHPG: -7.1 ± 1.5% of basal, P <0 . 0 1v sC H P G
alone in the hippocampus; MPEP + CHPG: -3.53 ± 0.44%
of basal, P < 0.05 vs CHPG alone in the striatum).
To investigate whether the activation of A2ARs could
have a facilitatory role on mGlu5R-mediated effects, CGS
21680, a selective A2AR agonist, was used. Combined
ineffective doses of CHPG and CGS 21680 (500 μM+
50 nM in the hippocampus; 750 μM + 30 nM in the
striatum) synergistically reduced the slope of fEPSPs
recorded in CA1 (-25.0 ± 5.4%, P < 0.005 vs basal) and
the amplitude of field potentials (FPs) recorded in the
dorsomedial striatum (-13.42 ± 2.7%, P < 0.05 vs basal),
whereas neither CGS 21680 nor CHPG affected synaptic
transmission on their own (Figure 1b). Both MPEP
(30 μM) and the selective A2AR antagonist ZM 241385
(100 nM) abolished the synergistic effect resulting from the
coactivation of A2A and mGlu5Rs (not shown).
Different mechanisms are involved in the A2A/mGlu5
interaction in the two brain areas
In order to explore the mechanisms underlying the
facilitatory role of CGS 21680 towards CHPG, the
influence of the adenylate cyclase activator forskolin and
of the protein kinase A (PKA) inhibitor KT5720 were
studied. Interestingly, the potentiating effect of CGS 21680
towards CHPG was reproduced by forskolin and abolished
by KT 5720 in corticostriatal but not in hippocampal slices.
Co-application for 10 min of forskolin (100 nM) and CHPG
induced a transient depression of the response (-17.99 ±
4.89% with respect to basal) in corticostriatal slices
(Figure 2a,b) Conversely, forskolin (up to 30 μM) failed to
potentiate CHPG responses in the hippocampus. Further-
more, the synergistic depression induced by CHPG plus
CGS 21680 was prevented by the PKA inhibitor KT 5720
(4 μM) only in the striatum. These results indicate an
involvement of the cyclic adenosine monophosphate
(cAMP)/PKA pathway in the A2A/mGlu5 interaction in the
striatum but not in the hippocampus.
A postsynaptic locus of interaction is more likely
in both the striatum and the hippocampus
Since both A2A and mGlu5Rs modulate glutamate release
[21–23], we wanted to establish the possible involvement
of presynaptic mechanisms in the effects of A2A and mGlu5
receptor agonists. To this end, a series of experiments was
performed under a protocol of paired pulse stimulation
(PPS), in which the afferents fibers were stimulated twice
with an interpulse interval of 50 ms. In control conditions,
such a protocol normally elicits a condition of paired pulse
facilitation (PPF), in which the response elicited by the
second stimulus (R2) is greater than the response elicited by
the first stimulus (R1). Modification of this phenomenon is
usually attributed to a presynaptic calcium-dependent
change in release probability at both excitatory and
inhibitory synapses. When PPF is increased by a drug, it
suggests an inhibition of release probability and when PPF
is decreased, up to a change in paired pulse depression
(PPD), it suggests a facilitation of release probability [24].
The degree of PPF is quantified by the R2/R1 ratio. The
application of CGS 21680 and/or CHPG did not modify the
Figure 2 A different mechanism is involved in the synergism
between A2A and mGlu5 receptors in hippocampal and corticostriatal
slices. The histograms show that the effect of CGS 21680 is mimicked
by the adenylyl cyclase activator forskolin (100 nM) and blocked by
the PKA inhibitor KT 5720 (4 μM) in the striatum (a) but not in the
hippocampus (b). The results are expressed as means ± SEM of 4–6
experiments. *P < 0.05 vs baseline (Wilcoxon signed rank test)
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both areas, data not shown). Thus, although a lack of effect
upon paired pulse stimulation does not allow to definitely
exclude a presynaptic locus of action, such a possibility
appears not very likely.
In both brain areas, the state of activation of A2A
receptor influences the ability of mGlu5Rs
to potentiate NMDA effects
Slice perfusion for 10 min with NMDA (8 and 12.5 μM)
induced a comparable reduction of the fEPSP slope
(≅27%) and of the FP amplitude (≅23%) in hippocampal
and corticostriatal slices, respectively. Such an effect was
stronglypotentiatedbytheapplicationofCHPG500–750μM
(286.6 ± 16.9% and 329.97 ± 38.68% of NMDA alone in the
hippocampus and in the striatum, respectively; P <0 . 0 5i n
both cases) (Figure 3a,b). In the hippocampus, the NMDA-
potentiating effect of CHPG was completely blocked by the
selective mGlu5R antagonist MPEP (30 μM) and signifi-
cantly attenuated by the A2AR antagonist ZM 241385 (30–
100 nM) (Figure 4a). When given alone, neither MPEP nor
ZM 241385 influenced the basal synaptic transmission or the
NMDA-induced inhibition of the fEPSP slope (not shown).
In the striatum, not only MPEP (30 μM) but also ZM
Figure 3 CHPG-potentiated NMDA effects in hippocampal and
corticostriatal slices. Graphs represent the time course of changes in
FP amplitude and fEPSP slope in two typical experiments recorded in
corticostriatal (a) and in hippocampal slices (b), respectively. A 10-
min superfusion period with NMDA (12.5 and 8 μM) reduced the
synaptic response, an effect that was potentiated by the co-application,
30 min later, of 750 μM (a) or 500 μM (b) CHPG. Each point rep-
resents the means of three responses evoked by stimulation of
afferents fibers in the two areas
Figure 4 The blockade of either A2A or mGlu5 receptors prevents the
ability of CHPG to potentiate NMDA effects in hippocampal and
corticostriatal slices. The histograms show that ineffective concen-
trations of CHPG (500–750 μM) significantly potentiated NMDA-
induced reduction in FP amplitude (a) or fEPSP slope (b) and that
both the mGlu5R antagonist MPEP (30 μM) and the A2A receptor
antagonist ZM241385 (30–100 nM) prevented the effects of CHPG.
All values are expressed as percentage of the NMDA effects and
represent the mean ± SEM values from 4–6 experiments in each
group. °P < 0.05 (Mann-Whitney U test) vs NMDA alone; *P < 0.05
(Mann-Whitney U test) vs CHP + NMDA
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tion of NMDA effects (P < 0.05 vs NMDA + CHPG,
Figure 4b). Interestingly, ZM 241385 alone did not influence
basal synaptic transmission nor did it directly inhibit NMDA
effects but instead, in agreement with previous observations
from our group [25], it tended to increase NMDA-induced
FP depression (165.91 ± 31.03%; P <0 . 0 5v sN M D A
alone).
A tone at A2ARs is required to allow mGlu5Rs
to potentiate NMDA toxicity
To evaluate whether the A2A/mGlu5 receptor interaction
also played a role in the modulation of NMDA-induced
toxicity, primary cultures of rat striatal and hippocampal
neurons were used. Neurons isolated from 17-day-old rat
embryos, plated in Neurobasal medium and grown in vitro
for 13–15 days, were used. Neuronal cell injury was
quantified by the measurement of lactate dehydrogenase
(LDH) released in the culture medium. Incubation for 1 h of
neuronal cultures with 300 µM NMDA induced a compara-
ble increase of LDH release in hippocampal (190.2 ± 32.4%)
and striatal cell cultures (170.3 ± 18.46). CHPG 1 mM
(ineffective by itself) significantly potentiated NMDA-
induced LDH release (312.4 ± 60.1% in the hippocampus;
249.5 ± 31.64% in the striatum; P < 0.05 vs NMDA alone).
The potentiating effect of CHPG on NMDA-induced LDH
release was prevented by both the A2A and mGlu5 receptor
antagonists. In fact, 15 min of pretreatment with MPEP
(30 μM) or ZM 241385 (30 nM) were able to restore the
same levels of LDH induced by NMDA alone (P < 0.05 vs
CHPG ± NMDA). When applied alone, neither MPEP nor
ZM 241385 influenced basal or NMDA-induced LDH
release (Figure 5).
Discussion
The main finding of this paper is that the mGlu5Rs, in the
two brain areas where they show the highest levels of
expression (namely, the striatum and the hippocampus), are
under the tight control of the adenosine A2ARs. Specifically,
A2ARs appear to exert both a facilitatory and a permissive
role on mGlu5R-mediated effects.
The facilitatory role played by A2ARs towards mGlu5R-
induced effects is demonstrated in hippocampal and
corticostriatal slices. The synergistic reduction of the fEPSP
slope in the hippocampus and of the FP amplitude in the
striatum observed after the co-application of ineffective
concentrations of CGS 21680 and CHPG was clearly
superimposable, as well as the effect elicited by higher
concentrations of CHPG (1 mM).
As for the mechanisms involved in the synergistic
A2A/mGlu5 receptor interaction, our results indicate the
involvement of different transduction pathways in the
striatum and hippocampus. Indeed, the potentiating effect
of CGS 21680 was reproduced by forskolin and abolished
by the PKA inhibitor KT 5720 in striatal but not in
hippocampal slices, thus indicating that only in the former
area does the A2A/mGlu5 interaction require the recruitment
of PKA. This finding is not so surprising since, although
the cAMP/PKA pathway is considered the canonical
transduction system operated by A2ARs [26], hippocampal
Figure 5 The blockade of either A2A or mGlu5 receptors prevents the
ability of CHPG to potentiate NMDA-induced LDH release from
cultured hippocampal and striatal neurons. The application of NMDA
(300 μM for 60 min) to both striatal and hippocampal neurons in-
duced a significant increase in LDH release. The mGlu5R agonist
CHPG (1 mM) was devoid of effects on its own, but it significantly
potentiated NMDA-induced LDH release. The mGlu5R antagonist
MPEP (30 μM) or the A2A receptor antagonist ZM 241385 (30 nM)
were devoid of effects by themselves but prevented the ability of
CHPG to potentiate the release of LDH. Results represent means ±
SEM values of 3–4 independent experiments, assayed in triplicate.
°P < 0.05 (Mann-Whitney U test) vs NMDA alone
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particular in the control of glutamatergic transmission [23,
27]. On the other hand, the demonstration of an involvement
of the cAMP/PKA pathway in the effects of striatal A2ARs
does not rule out other possible mechanisms, since A2ARs
can activate two signalling systems (one involving the
activation of PKA and the other mediated by PKC), also in
striatal nerve terminals [28]. However, we have not
attempted to test whether PKC might be involved in this
potentiation of mGlu5 responses by A2ARs, since the
manipulation of PKC activity is also expected to directly
affect the responses mediated by mGlu5Rs [29, 30].
Inthestriatum,bothA2A and mGlu5 receptors are mainly
localized postsynaptically [31, 32], although they have been
found to colocalize in glutamatergic nerve terminals [8]. In
the hippocampus, A2A and mGlu5 receptors are colocalized
in glutamatergic synapses and they are present both in the
presynaptic active zone and in the postsynaptic density,
although with different subsynaptic distribution [19]. In
spite of the ability of both A2A and mGlu5Rs to control the
presynaptic release of glutamate [8, 21–23, 33–35], the
findings obtained in both areas under a protocol of PPS
(namely, the inability of CHPG and CGS 21680 to
influence the R2/R1 ratio) suggest that the locus of their
interaction is most probably postsynaptic. This possibility is
reinforced by the predominant postsynaptic localization of
mGlu5Rs, in particular in the hippocampus (e.g., [19, 36–
38]), and by the finding that one of the main consequences of
the interaction between A2A and mGlu5 receptors is the
control of NMDA receptor-mediated effects (see below),
which is likely to occur postsynaptically, because the
postsynaptic density is the only neuronal compartment where
the three receptors are simultaneously present [19].
In both hippocampal and striatal slices, we confirmed the
previously reported potentiating effect of CHPG on NMDA-
induced depolarization [39–41]. In both areas we demon-
strated that the above effect was prevented not only by
MPEP but also by the A2AR antagonist ZM 241385.
Although the inhibitory effects of ZM 241385 were most
prominent in the striatum, one of the most interesting
observations was that the ability of CHPG to potentiate
NMDA responses requires an endogenous tone at A2A
receptors even in the hippocampus, i.e., a brain area in
which the expression of such receptors is rather low. This
was further strengthened by the finding that, in hippocampal
slices from A2AR knockout (KO) mice, CHPG was unable to
potentiate the fEPSP slope reduction induced by NMDA
[19]. Furthermore, it is important to note that WT and A2AR
KO mice showed similar responses to NMDA application,
thus indicating that A2AR inactivation does not directly
inhibit NMDA-mediated effects [19]. This is in agreement
with the finding that, in rat slices, ZM 241385 prevented the
potentiating effects of CHPG without directly inhibiting
NMDA effects. Rather, in agreement with previous studies
[25], we found that ZM 241385 tended to potentiate NMDA
effects in corticostriatal slices.
The permissive role played by A2ARs on mGlu5R-
mediated effects appears to be also relevant in the
modulation of NMDA-mediated toxicity. The findings
obtained in cell cultures indicate that CHPG significantly
potentiated NMDA-induced LDH release. This effect was
blocked by MPEP, thus confirming the selective involve-
ment of mGlu5Rs and, more interestingly, also by ZM
241385. This implies that the functional interaction be-
tween A2A and mGlu5Rs plays a significant role in the
modulation of NMDA-mediated toxicity, an effect which
could be particularly relevant in a region, such as the
hippocampus, extremely sensitive to excitotoxic insults.
Altogether the present results suggest that the state of
activation of A2A receptors may regulate the effects exerted
by mGlu5Rs in terms of both synaptic plasticity [3, 15] and
excitotoxicity [18, 42]. Another interesting implication is
that the neuroprotective effects of A2AR antagonists towards
neurodegeneration (see [43] for review) could be mediated
not only by their modulation of glutamate outflow, but also
by the removal of the permissive role of A2ARs on mGlu5R-
mediated toxicity. In conclusion, the ability of A2ARs to
control mGlu5R-dependent effects in different brain regions
irrespective of their density emphasizes the role of A2ARs as
a fine-tuning modulatory system [44] in the brain. These
results add further support to the idea that A2ARs might
represent an additional target for the development of ther-
apeutic strategies against neurological disorders associated
with NMDA receptor dysfunction.
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